ArticleScientific reports2026
Dynamic wavelet transform normalized multi scale dense attention UNet with Binary Horse Herd Optimization for osteosarcoma diagnosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is a highly aggressive primary bone cancer characterized by rapid progression and complex tissue heterogeneity, making accurate diagnosis and treatment planning particularly challenging. Conventional imaging-based diagnostic approaches often struggle to reliably differentiate viable tumor tissue, non-viable tumor regions, and healthy bone, leading to segmentation inaccuracies and elevated false-positive rates that can adversely affect clinical decision-making. To address these challenges, this work proposes DWT-N-MSDAUNet, a hybrid deep attention-based framework for precise osteosarcoma segmentation and multi-class classification.The proposed framework integrates Dynamic Wavelet Transform Normalization (DWT-N) for image enhancement, followed by a Multi-Scale Dense Attention U-Net (MSDA-UNet) to achieve accurate multiscale tumor segmentation. From the segmented representations, Binary Horse Herd Optimization (B-HHO) is employed to select the most discriminative features, reducing redundancy while preserving critical structural and textural information. Final classification into viable tumor, non-viable tumor, and healthy tissue classes is performed using a Bottleneck Transformer, optimized via the Puma Optimizer, to effectively model long-range spatial and contextual dependencies.The framework was evaluated on an osteosarcoma imaging dataset comprising approximately 1144labeled images, using fivefold cross-validation to ensure robustness and generalization. The MSDA-UNet achieved a Dice coefficient of 99.3% and a Jaccard index of 98.1%, with low boundary errors (ASSD = 0.3 mm, HD = 1.2 mm), outperforming UNet, UNet + + , Attention-UNet, and R2-UNet. The proposed Bottleneck Transformer classifier attained an overall accuracy of 99.5%, with precision, recall, and F1-scores above 99.5%, and a specificity of 99.55%, indicating a reduced false-positive rate. Class-wise evaluation further confirmed consistent performance across all tissue categories, with AUC values ranging from 0.96 to 0.98. Despite increased computational cost compared to lightweight models, the proposed approach demonstrated feasible deployment characteristics with an inference time of 63 ms per image, supporting its suitability for clinical diagnostic workflows. These results highlight the framework’s effectiveness in balancing high diagnostic accuracy with clinical reliability, particularly for biopsy guidance and treatment monitoring in osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.